مباشر
FierceBiotechExecutive Interviews at Fierce Biotech Week 2026BioWorldBiopharma money raised by month in 2026 (US$M)BioPharma DiveStudy data convince Lundbeck to push new migraine drug forwardBioPharma DiveGeneric drugmakers gain key victory in ‘skinny label’ patent caseEndpoints NewsInnovent declares Phase 3 success for ADC that attracted huge Takeda dealFierceBiotechAffibody gets izokibep ‘back on track’ while seeking ‘new home’ after drug’s Acelyrin rejectionClinical OMICsInfluenza Drugs Could Prevent Cognitive Decline in Chronic Viral InfectionsFierceBiotechInsulet debuts latest enhancements to popular Omnipod insulin delivery systemPharmaVoiceBMS under pressure in schizophrenia; Summit/Akeso on a winning streakPromega BlogMeasuring What Matters in Metabolic Research: A Bioluminescent ToolkitBioWorldNME Digest: Q1 2026FierceBiotechChutes & Ladders—AstraZeneca adds FDA cell and gene veteran
Cell ٦ يناير ٢٠٢٦

Extracellular GPX4 impairs antitumor immunity via dendritic ZP3 receptors

Extracellular GPX4 impairs antitumor immunity via dendritic ZP3 receptors

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.